Insulin, tPA AND PAI-I levels and their correlations with cardiac risk and disease factors in the hypertensive cohort of the appropriate blood pressure control in diabetes trial-part 2 with valsartan (ABCD-2V)
2000; Oxford University Press; Volume: 13; Issue: 6 Linguagem: Inglês
10.1016/s0895-7061(00)00508-2
ISSN1941-7225
AutoresMartin P. Bedigian, Raymond O. Estacio, Beckie Jeffers, Sean Biggerstaff, Robert W. Schrier,
Tópico(s)Pharmacology and Obesity Treatment
ResumoABCD-2V is a prospective, randomized trial comparing the effects of intensive versus moderate BP control on complications of type 2 diabetes using valsartan, an angiotensin receptor blocker (ARB), as the primary antihypertensive agent. We report the insulin, tPA, and PAI-1 levels of the hypertensive cohort at baseline prior to valsartan therapy. Insulin, tPA and PAI-1 levels were above normal values. PAI-1 and tPA levels were inversely correlated with HDL levels (r=−0.242 and −0.195 respectively, p 4 than scores 4 had longer duration of diabetes (16.8±7.2 yrs vs 14.5±7.0 yrs, p=0.019) than patients with scores <4. Higher insulin levels were also associated with overt albuminuria versus those with normo or microalbuminuria (1.5±0.2 ng/ml vs 1.1±0.1 ng/ml, p=0.04 or 1.1±0.2 ng/ml, p=0.07). Insulin, tPA and PAI-1 did not correlate with age, male gender, intensive versus moderate BP control, total cholesterol or LDL. Endothelial dysfunction, as indicated by elevations of plasma tPA and PAI-1, is associated with lower HDL levels in this cohort. Insulin levels may predict LVH and overt nephropathy in hypertensive diabetics. (See Table)
Referência(s)